00:00And Cuban President Miguel DÃaz-Canel met with public health experts and scientists to review Phase III clinical trial results
00:06for the domestic drug Jusvinsa in treating post-chikungunya arthritis.
00:11The findings validate the therapeutic efficacy of the Cuban-developed peptide in managing persistent joint inflammation.
00:18Developed by the Center for Genetic Engineering and Biotechnology, Jusvinsa has demonstrated significant clinical benefits for patients suffering from long
00:26-term inflammatory sequel following a viral infection, Cuban health officials emphasized that the success of the clinical trial reinforces the
00:37country's sovereign biotechnology sector, which continues to expand the therapeutic applications of the drug previously deployed against rheumatoid arthritis and
00:45severe inflammatory conditions during the COVID-19.
00:48Thank you very much.
